Ledermann JA - Search Results

1

The European Society for Medical Oncology (ESMO) Congress 2016: Highlights and summary of selected abstracts in gynecologic cancers.

Miller RE, Ledermann JA. Miller RE, et al. Among authors: ledermann ja. Gynecol Oncol. 2017 Jan;144(1):8-10. doi: 10.1016/j.ygyno.2016.11.040. Epub 2016 Nov 27. Gynecol Oncol. 2017. PMID: 27903404 No abstract available.

2

Targeted trials in ovarian cancer.

Ledermann JA, Raja FA. Ledermann JA, et al. Gynecol Oncol. 2010 Oct;119(1):151-6. doi: 10.1016/j.ygyno.2010.05.008. Epub 2010 Jun 29. Gynecol Oncol. 2010. PMID: 20591473 Review.

3

The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.

Miller RE, Ledermann JA. Miller RE, et al. Among authors: ledermann ja. Clin Adv Hematol Oncol. 2016 Aug;14(8):619-27. Clin Adv Hematol Oncol. 2016. PMID: 27487106 Review.

4

The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.

Miller RE, Ledermann JA. Miller RE, et al. Among authors: ledermann ja. Clin Adv Hematol Oncol. 2016 Sep;14(9):704-11. Clin Adv Hematol Oncol. 2016. PMID: 27673289 Review.

5

Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review.

Marchetti C, Kristeleit R, McCormack M, Mould T, Olaitan A, Widschwendter M, MacDonald N, Ledermann JA. Marchetti C, et al. Among authors: ledermann ja. Gynecol Oncol. 2017 Jan;144(1):57-60. doi: 10.1016/j.ygyno.2016.11.001. Epub 2016 Nov 5. Gynecol Oncol. 2017. PMID: 27825669 Free article.

6

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.

González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ; ICON7 investigators. González Martín A, et al. Among authors: ledermann ja. Gynecol Oncol. 2019 Jan;152(1):53-60. doi: 10.1016/j.ygyno.2018.08.036. Epub 2018 Nov 16. Gynecol Oncol. 2019. PMID: 30449719 Free PMC article. Clinical Trial.

7

Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?

Ledermann JA. Ledermann JA. Gynecol Oncol. 2019 May;153(2):213-214. doi: 10.1016/j.ygyno.2019.04.014. Gynecol Oncol. 2019. PMID: 31027611 No abstract available.

8

Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?

Miller RE, Crusz SM, Ledermann JA. Miller RE, et al. Among authors: ledermann ja. Future Oncol. 2019 Jun;15(16):1845-1853. doi: 10.2217/fon-2019-0057. Epub 2019 Apr 30. Future Oncol. 2019. PMID: 31037967

9

Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?

Gourley C, Miller RE, Hollis RL, Ledermann JA. Gourley C, et al. Among authors: ledermann ja. Curr Opin Oncol. 2020 Sep;32(5):442-450. doi: 10.1097/CCO.0000000000000660. Curr Opin Oncol. 2020. PMID: 32796232 Review.

10

Testing for homologous recombination deficiency - does it provide new insights for the use of veliparib?

Ledermann JA. Ledermann JA. Gynecol Oncol. 2022 Feb;164(2):243-244. doi: 10.1016/j.ygyno.2022.01.018. Gynecol Oncol. 2022. PMID: 35086648 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

217 results

Search Page